A top-5 pharmaceutical company sought the perspectives of payers in the US and major EU markets to ensure that the value of an innovative vaccine would ultimately be recognized by health systems.
The Ontario Brain Institute (OBI) needed to define its strategic direction and articulate its value to policymakers to ensure continued government support for brain research.
A top-5 pharmaceutical company needed to prepare decision-makers for the patient and health system impact of disease-modifying therapies and diagnostic biomarkers for Alzheimer’s disease.
A large institutional investment firm engaged Shift Health to evaluate the products in a portfolio of pharma royalties it had an opportunity to acquire.
The Saudi Government aimed to create a national health research agency to strengthen the research and innovation ecosystem, support a learning healthcare system and diversify the Kingdom’s knowledge economy.
Cancer research stakeholders across Canada recognized the need for a unifying vision that would inspire collective action and prepare Canada for leadership in a rapidly evolving cancer research landscape.
Shift Health was engaged to support a top-5 global pharmaceutical company in defining its role and priorities in the evolving HIV disease management landscape.
Shift Health and University Health Network (UHN) were engaged by Halton Healthcare to assess the current state of research across a multisite hospital system and define the future direction of its clinical research program.
A multinational pharmaceutical company sought support in developing a strategy to partner with public/academic cancer patient data repositories to advance its own R&D programs.